Susan Blaney
Overview
Explore the profile of Susan Blaney including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
591
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin F, Stuckert A, Tat C, White M, Ruggieri L, Zhang H, et al.
J Clin Oncol
. 2024 May;
42(23):2769-2779.
PMID: 38771986
Purpose: T cells modified with chimeric antigen receptors (CARTs) have demonstrated efficacy for hematologic malignancies; however, benefit for patients with CNS tumors has been limited. To enhance T cell activity...
2.
Chuk M, Widemann B, Minard C, Liu X, Kim A, Bernhardt M, et al.
Pediatr Blood Cancer
. 2018 Apr;
65(8):e27077.
PMID: 29693796
Background: We conducted a phase 1 trial to determine the maximum tolerated dose (MTD), toxicity profile, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of cabozantinib in children with refractory or...
3.
Leary S, Park J, Reid J, Ralya A, Baruchel S, Wu B, et al.
Clin Cancer Res
. 2017 Jul;
23(20):6062-6069.
PMID: 28751444
Trebananib is a first-in-class antiangiogenic peptibody (peptide-Fc fusion protein) that inhibits Angiopoietin 1 and 2. A pediatric phase 1 trial was performed to define trebananib dose-limiting toxicities (DLT), recommended phase...
4.
Boyers L, Schultz A, Baceviciene R, Blaney S, Marvi N, Dellavalle R, et al.
Telemed J E Health
. 2015 Jan;
21(4):312-4.
PMID: 25635528
Although teledermatology (TD) is regarded as a tool to improve patient access to specialty healthcare, little has been done to evaluate its role in medical education. We describe the TD...
5.
Bagatell R, Norris R, Ingle A, Ahern C, Voss S, Fox E, et al.
Pediatr Blood Cancer
. 2013 Nov;
61(5):833-9.
PMID: 24249672
Background: mTOR inhibitors have activity in pediatric tumor models. A phase I trial of the mTOR inhibitor temsirolimus (TEM) with irinotecan (IRN) and temozolomide (TMZ) was conducted in children with...
6.
Beaty 3rd O, Berg S, Blaney S, Malogolowkin M, Krailo M, Knight R, et al.
Pediatr Blood Cancer
. 2010 Jul;
55(3):440-5.
PMID: 20658614
Background: Platinating agents are used in the treatment of a spectrum of childhood cancers. Oxaliplatin, a third generation platinum compound, may provide less toxicity and be more effective. A phase...
7.
Kieran M, Supko J, Wallace D, Fruscio R, Poussaint T, Phillips P, et al.
Pediatr Blood Cancer
. 2008 Dec;
52(2):169-76.
PMID: 19065567
SU5416 is a novel small molecule tyrosine kinase inhibitor of the VEGF receptors 1 and 2. A phase I dose escalation study stratified by concurrent use (stratum II) or absence...
8.
Bradley K, Pollack I, Reid J, Adamson P, Ames M, Vezina G, et al.
Neuro Oncol
. 2008 Aug;
10(5):752-8.
PMID: 18715950
The purpose of this study was to determine the dose-limiting toxicities, maximum tolerated dose, pharmacokinetics, and intratumor and brain distribution of motexafin gadolinium (MGd) with involved field radiation therapy in...
9.
Bomgaars L, Thompson P, Berg S, Serabe B, Aleksic A, Blaney S
Pediatr Blood Cancer
. 2008 Jun;
51(4):504-8.
PMID: 18561175
Background: Valacyclovir, an orally administered pro-drug of acyclovir, is utilized in the therapy of herpes simplex and herpes zoster infections. Little data regarding the pharmacokinetics, safety and tolerability are available...
10.
Flanders Stepans M, Wilhelm S, Hertzog M, Rodehorst T, Blaney S, Clemens B, et al.
Breastfeed Med
. 2007 Jul;
1(4):207-15.
PMID: 17661601
A pilot study tested the relationship between human milk oligosaccharide consumption, oligosaccharide content of feces, and subsequent disease in breastfed infants. Forty-nine (49) mother-infant pairs provided milk and fecal samples...